Smoking Cessation and Nicotine Deaddiction Landscape Report 2024: Therapeutic Assessment of Novel Drug Candidates, Emerging Drugs and the Route to Commercialization

Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2024" report has been added to's offering.

The global commitment to advancing treatments for Smoking Cessation and Nicotine Deaddiction is gaining momentum, as highlighted in the latest comprehensive insight report for 2024. With an in-depth analysis of over five companies and as many pipeline drugs, the report delineates the disease overview, therapeutic assessment by product type, and current clinical stages in the pipeline landscape.

Therapeutic Assessment of Novel Drug Candidates

Novel approaches are at the forefront of research and development within this therapeutic area. The report underscores the clinical and commercial evaluation of pipeline drugs, providing invaluable information on the drug profiles that cover both clinical and nonclinical stage products. Through meticulous research, the report aids in understanding the intricacies of each proposed treatment, including their mechanism of action, clinical trial statuses, and developmental activities.

Focus on Innovation and Collaborative Efforts

Companies and academic institutions are diligently working to address challenges and capitalize on opportunities that may influence the trajectory of research and development in Smoking Cessation and Nicotine Deaddiction. Collaborations and innovative treatments are distinguished as pivotal components in the search for effective therapies.

Emerging Drugs and the Route to Commercialization

Among the standout therapies is Cytisinicline, developed by Achieve Life Sciences and currently in the Phase III stage of development. Additionally, NFL Biosciences' NFL 101 is progressing through the Phase II stage. Both therapies represent the potential to significantly reduce nicotine dependence. The report highlights therapies in various stages of development, from early-phase trials to more advanced Phase III studies.

Assessment of Pipeline Development Activities

A comprehensive section on pipeline development activities collates critical data on collaborations, mergers, acquisitions, and the therapeutic evaluations of emerging drugs. The report serves as a vital tool for stakeholders to grasp the dynamic nature of the landscape and the strategic movements within it.

Impact on Global Health and Unmet Needs

The Smoking Cessation and Nicotine Deaddiction landscape represents not just an area of intense scientific pursuit but also one that bears significant global health implications. The insights offered aim to inform and guide decisions in addressing the dire unmet needs of individuals grappling with nicotine dependence and its detrimental health outcomes.

The contribution of this report is pivotal as it provides a clear and concise summary of where the field of Smoking Cessation and Nicotine Deaddiction is heading, marking the crucial progress in addressing this pressing public health issue.

A selection of companies mentioned in this report includes, but is not limited to:

  • Achieve LifeSciences
  • NFL Biosciences
  • Axsome Therapeutics

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data